FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL			
OMB	3235-		
Number:	0104		
Estimated average			
burden hours per			
response	0.5		

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)							
1. Name and Address of Reporting				g 3. Issuer Name and Ticker or Trading Symbol			
Person *	Statement (Month/Day/Y	ear)	NAVIDEA	BIOPHARN	1ACEUTICA	LS, INC. [NAVB]	
GUETH ANTON	06/01/2015	Cai)					
(Last) (First) (Middle 5600 BLAZER	e) 00,01,2015	4. Relations		p of Reporting		5. If Amendment, Date Original Filed(Month/Day/Year)	
PARKWAY, SUITE 200			Person(s) to Issuer (Check all applicable) _X_DirectorOfficer (give title below) Filed(Month/Day/Year) Filed(Month/Day/Year) 6. Individual or Joint/ Filing(Check Applicable Liver)		Filed(Mo		
					C Y 11	1 1 1 1	
(Street)							
DUBLIN, OH 43017					_X_ Form	filed by One Reporting Person	
					Form Person	filed by More than One Reporting	
(City) (State) (Zip)		Table I	- Non-Derivati	ve Securities	S Beneficially	y Owned	
1.Title of Security						direct Beneficial	
(Instr. 4)			Beneficially Owned Ownership Ownership				
	((Instr. 4)		Form: Direct (D) or	(Instr. 5)		
				Indirect (I)			
				(Instr. 5)			
Common Stock		0 (1)		D			
Reminder: Report on a separate line	for each class of seco	urities be	neficially owned d	irectly or indir	ectly.	SEC 1473 (7-02)	
Persons who	respond to the c	ollection	n of information	contained in	n this form ar	e	
not required number.	not required to respond unless the form displays a currently valid OMB control					ı	
Table II - Derivative Se	curities Beneficially	y Owned	(e.g., puts, calls, v	varrants, opti	ons, convertib	1	
1. Title of Derivative Security	2. Date Exercisable		tle and Amount of	4. Conversion	5.	6. Nature of Indirect	
(Instr. 4)	Instr. 4) and Expiration Date (Month/Day/Year)		Securities Underlying Derivative Security			Beneficial Ownership (Instr. 5)	
	()	(Instr. 4)			Derivative	(msu. 5)	
	Date Expirat			Derivative	Security:		
	Exercisable Date		Amount or Numb	Security	Direct (D) or Indirect		
		Title	of Shares		(I)		
					(Instr. 5)		
						•	
Danauting Oxynama							

Reporting Owners

Reporting Owner Name / Address	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
GUETH ANTON 5600 BLAZER PARKWAY	X				
SUITE 200 DUBLIN, OH 43017					

Signatures

William J. Kelly, attorney-in-fact	06/04/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) No securities are beneficially owned.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Power of Attorney

Know all by these presents, that the undersigned hereby constitutes and appoints each of Brent L. Larson and William J. Kelly, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a director of Navidea Biopharmaceuticals, Inc. (the "Company"), a Form ID, Forms 3, 4, and 5 and any other documents necessary to facilitate the filing of reports in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID or Forms 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of June, 2015.

Signature /s/ Anton Gueth

Print Name Anton Gueth